Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jul 26;7(7):CD011773.
doi: 10.1002/14651858.CD011773.pub2.

Procarbazine, lomustine and vincristine for recurrent high-grade glioma

Saurabh Parasramka  1 , Goutham Talari, Myrna Rosenfeld, Jing Guo, John L Villano
Affiliations
Meta-Analysis

Procarbazine, lomustine and vincristine for recurrent high-grade glioma

Saurabh Parasramka et al. Cochrane Database Syst Rev. .

Abstract

Background: Recurrent high-grade glioma (HGG) carries an extremely poor prognosis. There is no current standard of care or guideline-based recommendations. Nitrosourea-based multidrug chemotherapy or PCV - procarbazine, lomustine (CCNU) and vincristine - is one of the treatment options at recurrence. There has been no meta-analysis which looks at the benefits and harms of PCV chemotherapy in adults with recurrent HGG.

Objectives: To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma. To investigate whether predefined subgroups of people benefit more or less from chemotherapy.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 4, 2017), MEDLINE (1946 to 22 May 2017), and Embase (1980 to 22 May 2017). We searched trial registries including the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; apps.who.int/trialsearch) and the National Institutes of Health (NIH; ClinicalTrials.gov). We searched the reference lists of all identified studies; the electronic table of contents of the Journal of Neuro-Oncology (1983 to 2016) and Neuro-Oncology (1999 to 2016); and conference abstracts from the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO 2004 to 2016). We also searched unpublished grey literature and other regional databases. There were no language restrictions.

Selection criteria: Randomised controlled trials (RCTs), quasi-randomised trials (QRCTs), or controlled clinical trials (CCTs) where PCV was used to treat adults with recurrent HGG. Comparison arm included no chemotherapy, other second line chemotherapy or best supportive care.

Data collection and analysis: Two review authors extracted the data and undertook a 'Risk of bias' assessment and critical appraisal of the studies.

Main results: We identified two RCTs meeting our inclusion criteria. The two trials tested different comparisons.One RCT included 35 participants and compared PCV with 'eight drugs in one day' multidrug chemotherapy, which is a combination of drugs with different mechanisms of action. Median survival was 6 months for the PCV group and 6.5 months for the 'eight drugs in one day' group. Adverse event outcomes were not graded or quantified. Progression-free survival (PFS) and quality of life (QoL) were not described in the methods and were not an outcome of interest. The sample size in this study was small, which lead to insufficient statistical power to detect clinical differences. According to the GRADE approach we judged the quality of evidence to be low for survival outcome and very low for chemotherapy toxicityThe second multi-institutional RCT included 447 participants and compared PCV with Temozolomide (TMZ). Participants were randomised into three arms to receive PCV, and two different regimens of TMZ in a 2:1:1 ratio at first recurrence. The trial reported a median overall survival of 6.7 months and 7.2 months for the PCV and TMZ group respectively. It reported a PFS of 3.6 months for the PCV group and 4.7 months for the TMZ group. There was no observed difference of effect on overall survival (hazard ratio (HR) 0.91, 95% CI 0.74 to 1.11; P = 0.35) or PFS (HR 0.89, 95% CI 0.73 to 1.08; P = 0.23) in participants receiving PCV or TMZ chemotherapy. The proportion of people with at least one grade 3 or 4 adverse event was not clinically important at 9.2% versus 12.2% in PCV and TMZ arms respectively. Mean QoL scores calculated at baseline, 12 weeks and 24 weeks was 51.9 versus 59.8 favouring TMZ (P = 0.04) which is statistically but not clinically significant and was less than the pre-defined 10 point change for moderate improvement. We judged the GRADE quality of evidence to be moderate for overall survival, PFS, and chemotherapy toxicity and low for QoL.

Authors' conclusions: Evidence is based on a single large trial analysis as the other trial was small, with inadequate power to detect survival difference. Chemotherapy-naive patients with HGG at first recurrence when treated with PCV or TMZ have similar survival and time-to-progression outcomes. Adverse events are similar and QoL scores are statistically but not clinically significant between TMZ and PCV. Further RCTs should be conducted with adequate power following CONSORT guidelines with emphasis on QoL outcomes.

PubMed Disclaimer

Conflict of interest statement

John L Villano: none known. Myrna Rosenfeld: none known. Saurabh Parasramka: none known. Goutham Talari: none known. Jing Guo: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item for each included study.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Boiardi 1992 {published data only}
    1. Boiardi A, Silvani A, Milanesi I, Broggi G, Fariselli L. Efficacy of '8‐drugs‐in‐one‐day' combination in treatment of recurrent GBM patients. Journal of Neuro‐Oncology 1992; Vol. 12, issue 2:153‐8. - PubMed
Brada 2010 {published data only}
    1. Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high‐grade glioma. Journal of Clinical Oncology 2010; Vol. 28, issue 30:4601‐8. - PubMed

References to studies excluded from this review

Bogdahn 2010 {published data only}
    1. Bogdahn U, Stockhammer G, Mahapatra AK, Venkataramana NK, Oliushine VE, Parfenov VE, et al. Pseudoprogression after treatment with the TGF‐beta 2 inhibitor trabedersen in high‐grade glioma patients. Journal of Clinical Oncology 2010;28:abstr 2054.
Boiardi 2001 {published data only}
    1. Boiardi A, Eoli M, Salmaggi A, Zappacosta B, Fariselli L, Milanesi I, et al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. Journal of Neuro‐Oncology 2001;54(1):39‐47. - PubMed
Bower 1997 {published data only}
    1. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high‐grade glioma. Cancer Chemotherapy and Pharmacology 1997;40(6):484‐8. - PubMed
Galanis 1998 {published data only}
    1. Galanis E, Buckner JC, Burch PA, Schaefer PL, Dinapoli RP, Novotny PJ, et al. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. Journal of Clinical Oncology 1998;16(9):2953‐8. - PubMed
Gilbert 2005 {published data only}
    1. Gilbert M, Campone M, Brandes AA, Gertler S, Green S, Fowst C, et al. Phase II/III randomized study of edotecarin vs. temozolomide or nitrosourea in patients with recurrent glioblastoma (GBM): Phase II results. EJC Supplements 2005;3(2):136.
Gutin 1975 {published data only}
    1. Gutin PH, Wilson CB, Kumar ARV, Boldrey E, Levin V, Powell M, et al. Phase II study if procabazine, and vincristine combination chemotheraoy in the treatment of malignant brain tumors. Cancer 1975;35(5):1398‐404. - PubMed
Levin 1980 {published data only}
    1. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, et al. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treatment Reports 1980;64(2‐3):237‐41. - PubMed
Shapiro 1976 {published data only}
    1. Shapiro WR, Young DF. Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride. Transactions of the American Neurological Association 1976;101:217‐20. - PubMed
Van den Bent 2003a {published data only}
    1. Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, et al. Second‐line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of Oncology 2003;14(4):599‐602. - PubMed
Wick 2009 {published data only}
    1. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA‐04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.. Journal of Clinical Oncology 2009;27(35):5874‐80. - PubMed
Yung 2000 {published data only}
    1. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer 2000;83(5):588‐93. - PMC - PubMed

References to ongoing studies

ChiCTR‐OOC‐15005759 2015 {published data only}
    1. ChiCTR‐OOC‐15005759. A study to evaluate the safety and effectiveness of PCV chemotherapy in patients with recurrent high‐grade glioma with IDH1/2 mutation. ClinicalTrials.gov 2015.

Additional references

Abdulkarim 2014
    1. Abdulkarim B, Lecavalier‐Barsoum M, Quon H. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD007104.pub2] - DOI - PMC - PubMed
Arismendi‐Morillo 2005
    1. Arismendi‐Morillo G, Castellano A. Tumoral micro‐blood vessels and vascular microenvironment in human astrocytic tumors. A transmission electron microscopy study. Journal of Neuro‐Oncology 2005;73(3):211‐7. - PubMed
Boyle 2004
    1. Boyle FM, Eller SL, Grossman SA. Penetration of intra‐arterially administered vincristine in experimental brain tumor. Journal of Neuro‐Oncology 2004;6(4):300‐6. - PMC - PubMed
Brandes 2002
    1. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 2002;58(12):1759‐64. - PubMed
Brooks 1984
    1. Brooks DJ, Beaney RP, Lammertsma AA, Leenders KL, Horlock PL, Kensett MJ, et al. Quantitative measurement of blood‐brain barrier permeability using rubidium‐82 and positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 1984;4(4):535‐45. - PubMed
Buckner 1995
    1. Buckner JC, Brown LD, Kugler JW, Cascino TL, Krook JE, Mailliard JA, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. Journal of Neurosurgery 1995;82(3):430‐5. - PubMed
Cairncross 2012
    1. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long‐term results of RTOG 9402. Journal of Clinical Oncology 2012;31(3):337‐43. - PMC - PubMed
CTCAE 2010
    1. The Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, version 4.0, 2010. evs.nci.nih.gov/ftp1/CTCAE/About.html (accessed 13 June 2015).
Eisele 2013
    1. Eisele G, Weller M. Targeting apoptosis pathways in glioblastoma. Cancer Letters 2013;332(2):335‐45. - PubMed
Ferlay 2015
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015;136(5):E359‐86. - PubMed
Hart 2013
    1. Hart M, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD007415.pub2] - DOI - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hildebrand 2005
    1. Hildebrand J, Lecaille C, Perennes J, Delattre J. Epileptic seizures during follow‐up of patients treated for primary brain tumors. Neurology 2005;65(2):212‐5. - PubMed
Kappelle 2001
    1. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, Bent MJ, Groeningen CJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 2001;56(1):118‐20. - PubMed
Khasraw 2014
    1. Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high‐grade glioma. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD008218.pub3] - DOI - PubMed
Louis 2007
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007;114(2):97‐109. - PMC - PubMed
Louis 2016
    1. Louis DN, Perry A, Reifenberger G, Deimling A, Figarella‐Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica 2016;131(6):803‐20. - PubMed
Macdonald 1990
    1. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology 1990;8(7):1277‐80. - PubMed
Mauer 2008
    1. Mauer ME, Bottomley A, Taphoorn MJB. Evaluating health‐related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. Current Opinion in Neurology 2008;21(6):745‐53. - PubMed
Ostrom 2013
    1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006‐2010. Neuro‐oncology 2013;15 Suppl 2:ii1‐56. - PMC - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Rajan 1994
    1. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. European Journal of Cancer (Oxford, England : 1990) 1994;30A(12):1809‐15. - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schmidt 2006
    1. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587‐9. - PubMed
Siegel 2012
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a Cancer Journal for Clinicians 2012;62(1):10‐29. - PubMed
Stupp 2005
    1. Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352(10):987‐96. - PubMed
Triebels 2004
    1. Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, et al. Salvage PCV chemotherapy for temozolomide‐resistant oligodendrogliomas. Neurology 2004;63(5):904‐6. - PubMed
Van den Bent 2012
    1. Bent M, Brandes A, Taphoorn M, Kros J, Kouwenhoven M, Delattre J, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long‐term follow‐up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 2012;31(3):344‐50. - PubMed
Van den Bent 2016
    1. Bent MJ, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co‐deletion: An Intergroup trial. Journal of Clinical Oncology 2016;34(suppl):abstr‐LBA2000.
Villano 2012
    1. Villano J, Letarte N, Yu J, Abdur S, Bressler L. Hematologic adverse events associated with temozolomide. Cancer Chemotherapy and Pharmacology 2012;69(1):107‐13. - PubMed
Wang 2013
    1. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Letters 2013;331(2):139‐46. - PubMed
Wen 2010
    1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high‐grade gliomas: response assessment in Neuro‐Oncology Working Group. Journal of Clinical Oncology 2010; Vol. 28, issue 11:1963‐72. - PubMed

Publication types

MeSH terms

LinkOut - more resources